Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Enterprise Value (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Enterprise Value for 16 consecutive years, with -$144.7 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 36.22% to -$144.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$144.7 million through Dec 2025, up 36.22% year-over-year, with the annual reading at -$144.7 million for FY2025, 36.22% up from the prior year.
  • Enterprise Value hit -$144.7 million in Q4 2025 for Perspective Therapeutics, up from -$321.5 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$9.2 million in Q4 2023 to a low of -$354.3 million in Q2 2025.
  • Historically, Enterprise Value has averaged -$127.8 million across 5 years, with a median of -$62.8 million in 2021.
  • Biggest five-year swings in Enterprise Value: plummeted 3079.9% in 2021 and later skyrocketed 78.89% in 2023.
  • Year by year, Enterprise Value stood at -$60.4 million in 2021, then grew by 27.5% to -$43.8 million in 2022, then surged by 78.89% to -$9.2 million in 2023, then crashed by 2356.33% to -$226.9 million in 2024, then skyrocketed by 36.22% to -$144.7 million in 2025.
  • Business Quant data shows Enterprise Value for CATX at -$144.7 million in Q4 2025, -$321.5 million in Q3 2025, and -$354.3 million in Q2 2025.